Publications & Presentations – I-Mab | Pioneering the Next Generation of Immuno-Oncology

About

Who We Are
A dynamic global biotech company

Value Creation
Laser-focused on delivering innovative therapies to patients in need

Leadership Team
A world-class global leadership team

People & Culture
People are the cornerstone of our success

Commitment to ESG
Committed to the highest environmental, social and governance standards
Innovation

Science
Our cutting-edge science focuses on fine-tuning the immune network in cancer

Publications & Presentations
A compilation of our latest publications and presentations

Operations
An integrated research, development, manufacturing and commercialization strategy
Products

Product Pipeline
We have an innovative and advanced immuno-oncology clinical pipeline

Clinical Trials
We work closely with global investigators to carefully conduct and monitor clinical studies
Partnerships
News & Events

News
Our Latest News

Events
Our Latest Events

Lemzoparlimab (TJC4)

Combination of lemzoparlimab and HER2-ADC elicits enhanced activity against HER2 expressing tumors

Download "Poster presentation at the 2022 SITC Meeting" PDF

Lemzoparlimab, a Novel Anti-CD47 Monoclonal Antibody, in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): Initial Clinical Results

Download "Proffered paper presentation at the 2022 ESMO meeting" PDF

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin’s Lymphoma: Initial Clinical Results

Download "Poster presentation at the 2021 ASH meeting" PDF

A first-in-patient study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

Download "Poster presentation at the 2020 SITC Meeting" PDF

TJC4, A Differentiated RBC Sparing Anti-CD47 Antibody for Anti-Cancer Therapy

Download "Poster presentation at the 2019 ASH meeting" PDF

A differentiated CD47 therapeutic antibody recognizing a novel epitope and sparing erythrocytes and platelets

Download "Poster presentation at the 2017 EACR meeting" PDF

Uliledlimab (TJD5)

Revealing Novel Immune Modulatory Mechanism of Uliledlimab through the Blockade of CD73 Pathway

Download "Poster presentation at the 2022 SITC Meeting" PDF

The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer

Download "Poster presentation at the 2021 ASCO meeting" PDF

TJ-CD4B

TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

Download "Poster presentation at the 2021 SITC meeting" PDF

Claudin 18.2 – 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation

Download "Poster presentation at the 2020 AACR meeting" PDF

Efineptakin alfa (TJ107)

A Phase I/IIa, Open-label, Dose-Escalation and Dose Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors

Download "Poster presentation at the 2019 SITC meeting" PDF

TJ-C64B

Discovery of a novel Claudin6-4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation

Download "Poster presentation at the 2022 AACR meeting" PDF

Enoblituzumab (TJ271)

Inhibition of B7-H3 by Enoblituzumab Elicits Antitumor Immune Modulation in Both Innate and Adaptive Immunity

Download "Poster presentation at the 2022 AACR meeting" PDF

TJ-C4GM

A novel immunocytokine fusion protein combining tumor-targeting anti-CD47 antibody with GM-CSF cytokine for enhanced anti-tumor efficacy

Download "Poster presentation at the 2018 AACR meeting" PDF

TJ-L1I7

A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes

Download "Poster presentation at the 2019 SITC meeting" PDF